| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/26/1999 | CA2321958A1 Method of producing mouse and human endostatin |
| 08/26/1999 | CA2321929A1 Methods for treatment of diabetes using peptide analogues of insulin |
| 08/26/1999 | CA2321814A1 Small molecules that increase the conversion of food to body weight gain |
| 08/26/1999 | CA2321262A1 Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor |
| 08/26/1999 | CA2321224A1 Phosphodiesterase 10 |
| 08/26/1999 | CA2321199A1 Compositions and methods for regulating lymphocyte activation |
| 08/26/1999 | CA2321197A1 Agents for the prevention of damages caused by stress conditions |
| 08/26/1999 | CA2321186A1 Apoptosis inducing molecule ii and methods of use |
| 08/26/1999 | CA2321165A1 Antibodies against human cd40 |
| 08/26/1999 | CA2321140A1 Inhibitors of complement activation |
| 08/26/1999 | CA2321104A1 Azole peptidomimetics as thrombin receptor antagonists |
| 08/26/1999 | CA2321102A1 Regulation of estrus and ovulation in gilts |
| 08/26/1999 | CA2321101A1 Modified heat shock protein-antigenic peptide complex |
| 08/26/1999 | CA2320808A1 Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 08/26/1999 | CA2320799A1 Secreted proteins and polynucleotides encoding them |
| 08/26/1999 | CA2320632A1 Caf1-related protein |
| 08/26/1999 | CA2320060A1 Skin care compositions |
| 08/26/1999 | CA2319039A1 Biotin-binding receptor molecules |
| 08/26/1999 | CA2319038A1 Analgesic peptides from venom of grammostola spatulata and use thereof |
| 08/26/1999 | CA2318811A1 Modulation of cell proliferation, methods and reagents |
| 08/26/1999 | CA2318394A1 Novel antibacterial agents |
| 08/26/1999 | CA2263703A1 A process for producing enteric coated pancreatin granules |
| 08/25/1999 | EP0937982A2 Diagnostic and therapeutic agent for treatment of autoimmune hepatitis |
| 08/25/1999 | EP0937779A2 Cell damage marker |
| 08/25/1999 | EP0937777A2 GABA receptors and their uses |
| 08/25/1999 | EP0937463A1 Skin care compositions |
| 08/25/1999 | EP0937461A1 Use of mk family as hematopoietic factor |
| 08/25/1999 | EP0937456A1 Erythropoietin liposomal dispersion |
| 08/25/1999 | EP0937153A1 Human monoclonal antibodies specific for hepatitis c virus (hcv) e2 antigen |
| 08/25/1999 | EP0937148A1 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| 08/25/1999 | EP0937147A1 Human natural killer cell activating factor ii |
| 08/25/1999 | EP0937146A2 Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
| 08/25/1999 | EP0937145A1 Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| 08/25/1999 | EP0937144A1 Human eosinophil-derived basic protein |
| 08/25/1999 | EP0937143A2 Secreted proteins and polynucleotides encoding them |
| 08/25/1999 | EP0937142A2 Secreted proteins and polynucleotides encoding them |
| 08/25/1999 | EP0937141A1 Polynucleotides encoding secreted proteins from human dendritic cells |
| 08/25/1999 | EP0937140A2 Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| 08/25/1999 | EP0937104A1 Endothelium specific expression regulated by epcr control elements |
| 08/25/1999 | EP0937103A2 Compounds and methods for modulating cell adhesion |
| 08/25/1999 | EP0937102A1 Human monocyte chemotactic proprotein |
| 08/25/1999 | EP0937101A1 Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them |
| 08/25/1999 | EP0937099A1 Oligomers which inhibit the expression of interleukin genes |
| 08/25/1999 | EP0937095A1 Targeted cytolysis of cancer cells |
| 08/25/1999 | EP0937073A2 Selective factor xa inhibitors |
| 08/25/1999 | EP0937042A1 Heteroaryl succinamides and their use as metalloproteinase inhibitors |
| 08/25/1999 | EP0936919A2 VARIANTS OF HUMAN CILIARY NEUROTROPHIC FACTOR (hCNTF) WITH A RANGE OF ACTION DIFFERENT FROM THAT OF THE WILD-TYPE MOLECULE |
| 08/25/1999 | EP0936918A1 Combination therapy for treatment of arthritic diseases |
| 08/25/1999 | EP0936914A1 Hydroxy-phosphinyl derivatives useful as naaladase inhibitors |
| 08/25/1999 | EP0781436A4 System and method of automatically generating chemical compounds with desired properties |
| 08/25/1999 | EP0755405B1 Phosphonyldipeptides useful in the treatment of cardiovascular diseases |
| 08/25/1999 | EP0723451B1 Use of lithium compounds in combination with ace-inhibitors and/or angiotensin ii -receptor antagonist for treating high blood pressure |
| 08/25/1999 | EP0682706B1 Novel compounds |
| 08/25/1999 | EP0661967B1 Combined virustatic antimediator (covam) treatment of common colds |
| 08/25/1999 | EP0646016B1 Synthetic peptides for the treatment of myasthenia gravis |
| 08/25/1999 | EP0602211B1 Use of growth factor igf-ii for the treatment of gastrointestinal disorders |
| 08/25/1999 | EP0237545B2 Production of pluripotent granulocyte colony-stimulating factor |
| 08/25/1999 | CN1226930A Antisense base sequences |
| 08/25/1999 | CN1226929A Valtage-gated calcium channel antagonist and methods |
| 08/25/1999 | CN1226927A Preparation of ionically cross-linked polyphosphazene microspheres by coacervation |
| 08/25/1999 | CN1226926A Plasminogen Activator capable of being activated by thrombin |
| 08/25/1999 | CN1226899A Synthetic IL-10 analogues |
| 08/25/1999 | CN1226898A Peptides promoting activation of latent TGF-'beta' and method for screening TGF-'beta' activity regulators |
| 08/25/1999 | CN1226897A Isolated peptides derived from mage-2 |
| 08/25/1999 | CN1226896A Modulating activity of hormones or their receptors-peptides, antibodies, vaccines and uses thereof |
| 08/25/1999 | CN1226842A Preservation by foam formation |
| 08/25/1999 | CN1226839A Methods and compositions for treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| 08/25/1999 | CN1226835A -i gene transfer methods for wound healing |
| 08/25/1999 | CN1226832A Atrial natriuretic peptide (ANP) as additive to peritoneal dialysis solutions |
| 08/25/1999 | CN1226827A Amino acid compositions and use thereof in immunosuppression |
| 08/25/1999 | CN1044781C 复方免疫抗生素 Immune antibiotic compound |
| 08/24/1999 | US5942663 Transformed biological protein |
| 08/24/1999 | US5942620 Methods for producing novel conjugates of thrombin inhibitors |
| 08/24/1999 | US5942607 B7-2: a CTLA4/CD28 ligand |
| 08/24/1999 | US5942602 Growth factor receptor antibodies |
| 08/24/1999 | US5942600 Compounds with selective control of fungal organism candida albicans for treatment in humans, for example those with weakened immune systems due to aids; species-specific control |
| 08/24/1999 | US5942599 Oligopeptide analog of carboxy terminus of complement protein; has constrained backbone beta-turn conformation; binds to receptor and is agonist of biological activity; for therapy of immunocompromised/immunodeficient patients |
| 08/24/1999 | US5942512 Method and composition for treating erectile dysfunction |
| 08/24/1999 | US5942499 Method of promoting bone growth with hyaluronic acid and growth factors |
| 08/24/1999 | US5942496 Methods and compositions for multiple gene transfer into bone cells |
| 08/24/1999 | US5942494 Increasing level of chaperone protein in cell by contacting with cysteine protease inhibitor; for treatment of extreme temperature exposure, athlerosclerosis, anoxia; antiischemic agents, antihypoxic agents |
| 08/24/1999 | US5942492 Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| 08/24/1999 | US5942491 Method and compositions for treating arthritis |
| 08/24/1999 | US5942489 Polypeptides with prolonged antagonistic duration; for treatment of diabetic retinopathy and nephropathy, and acromegaly; anticarcinogenic agents where cancer has somatomedin receptors |
| 08/24/1999 | US5942488 Mutant human beta-globin modified to contain at leaset two non-wild type amino acid residues; enhanced bicarbonate effect |
| 08/24/1999 | US5942487 Composition for treating cornea |
| 08/24/1999 | US5942434 Regulatory sequence from phophoglycerate kinase operably linked to coding sequence of exogenous gene; for gene therapy; in situ expression of enzymes which convert prodrugs to active anticarcinogenic/antitumor drugs or cytokines |
| 08/24/1999 | US5942433 Dna coding for a nucleic acid binding protein with n-terminal modified by addition of acidic amino acids forming domain for stable dimerization or multimerization with cell proteins; for controlling transcription factors by gene therapy |
| 08/24/1999 | US5942429 DEAH-box proteins |
| 08/24/1999 | US5942420 Nucleic acid which encodes a follistatin module containing protein; antiproliferative agent and anticarcinogenic agent |
| 08/24/1999 | US5942419 RsbW-1 encoding nucleic acids |
| 08/24/1999 | US5942417 CD44-like protein and nucleic acids |
| 08/24/1999 | US5942416 Treatment of infections from bacteria using polypeptides and polynucleotides |
| 08/24/1999 | US5942413 Polynucleotide fragment that codes an antigen from parasitic worms; antihelmintics |
| 08/24/1999 | US5942412 Polynucleic acid encoding variant insulin-like growth factor I receptor beta subunit and receptor |
| 08/24/1999 | US5942405 Identifying compounds which inhibit complement receptors by mixing cells expressing surface complement receptors with a labeled compound capable of binding receptor and determining if compound inhibits interactions by signal generation |
| 08/24/1999 | US5942404 Diagnosing leukemia by incubating cells with specific antibodies and detecting surface antigens |
| 08/24/1999 | US5942403 Compounds and methods for the detection of t. cruzi infection |
| 08/24/1999 | US5942399 Encoded by polynucleotide |
| 08/24/1999 | US5942389 Developing a genetic suppressor protein with resistance to platinum-based cytotoxic drugs; synthesizing random cdna fragments, transferring dna into expression vector, transducing eukaryotic cells and isolating modified cells |